EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer.

Mol Oncol · 2025 · PMC12591323 · PMID 40808640

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

This effect was already evident at T48 and T72, showing borderline significance compared to controls.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.